View in EDS HTML Full Text PDF Full Text

Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.

Saved in:
Bibliographic Details
Title: Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Authors: Lodise T; Albany College of Pharmacy and Health Sciences, Albany, NY, USA., Guo A; HEOR & RWE, Medical Affairs, Ferring Pharmaceuticals, Inc., 100 Interpace Parkway, Parsippany, NJ, 07054, USA. amy.guo@ferring.com., Yang M; Analysis Group, Boston, MA, USA., Cook EE; Analysis Group, Boston, MA, USA., Song W; Analysis Group, Boston, MA, USA., Yang D; Analysis Group, Boston, MA, USA., Wang Q; Analysis Group, London, UK., Zhao A; Analysis Group, Boston, MA, USA., Bochan M; Outpatient Integrated Strategies, Carmel, IN, USA.
Source: Advances in therapy [Adv Ther] 2023 Jun; Vol. 40 (6), pp. 2784-2800. Date of Electronic Publication: 2023 Apr 24.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37093359
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lodise+T%22">Lodise T</searchLink>; Albany College of Pharmacy and Health Sciences, Albany, NY, USA.<br /><searchLink fieldCode="AU" term="%22Guo+A%22">Guo A</searchLink>; HEOR & RWE, Medical Affairs, Ferring Pharmaceuticals, Inc., 100 Interpace Parkway, Parsippany, NJ, 07054, USA. amy.guo@ferring.com.<br /><searchLink fieldCode="AU" term="%22Yang+M%22">Yang M</searchLink>; Analysis Group, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Cook+EE%22">Cook EE</searchLink>; Analysis Group, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Song+W%22">Song W</searchLink>; Analysis Group, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Yang+D%22">Yang D</searchLink>; Analysis Group, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Q%22">Wang Q</searchLink>; Analysis Group, London, UK.<br /><searchLink fieldCode="AU" term="%22Zhao+A%22">Zhao A</searchLink>; Analysis Group, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bochan+M%22">Bochan M</searchLink>; Outpatient Integrated Strategies, Carmel, IN, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228611864%22">Advances in therapy</searchLink> [Adv Ther] 2023 Jun; Vol. 40 (6), pp. 2784-2800. <i>Date of Electronic Publication: </i>2023 Apr 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Health+Communications+Inc%22">Health Communications Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8611864 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1865-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220741238X%22">0741238X </searchLink><i>NLM ISO Abbreviation: </i>Adv Ther
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37093359
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s12325-023-02505-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2784
    Titles:
      – TitleFull: Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lodise T
      – PersonEntity:
          Name:
            NameFull: Guo A
      – PersonEntity:
          Name:
            NameFull: Yang M
      – PersonEntity:
          Name:
            NameFull: Cook EE
      – PersonEntity:
          Name:
            NameFull: Song W
      – PersonEntity:
          Name:
            NameFull: Yang D
      – PersonEntity:
          Name:
            NameFull: Wang Q
      – PersonEntity:
          Name:
            NameFull: Zhao A
      – PersonEntity:
          Name:
            NameFull: Bochan M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2023 Jun
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1865-8652
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Advances in therapy
              Type: main
ResultId 1